TP53 and head and neck squamous cell carcinoma: In summary, while TP53 mutations and methylation-based ctDNA biomarkers hold significant promise for improving the diagnostic and prognostic evaluation of HPV-negative HNSCC, their integration into routine clinical practice is still premature.